Skip to main content
LABT
NASDAQ Life Sciences

Lakewood-Amedex Pays $1.27M Cash to Retire All Series C Preferred

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.402
Mkt Cap
$985.791K
52W Low
$0.169
52W High
$98.2
52W Position info
138% above low
Off High info
100% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

LABT has more than doubled off its 52-week low of $0.169 on light trading volume (0.3× avg).

Summary

Lakewood-Amedex redeemed all 127,097 Series C Preferred shares for $1,270,970 in cash, eliminating the conversion overhang and all preferred stock, but consuming a meaningful chunk of its cash on hand.


Key Events · Financing and Capital Events · LABT

  • Series C Preferred Fully Redeemed

    Company redeemed all 127,097 outstanding Series C Preferred shares at $10.00 face value for an aggregate $1,270,970, paid in cash from available funds; the redemption closed November 4, 2026 and the shares were cancelled and returned to treasury.

  • Conversion Overhang Eliminated

    No Series C Preferred remains outstanding, so no additional common shares are issuable on conversion, and the company reports no preferred stock and no outstanding indebtedness for borrowed money.

  • Cash Runway Reduced

    The $1,270,970 was funded from cash on hand; the company's own risk disclosure notes the use of cash for the redemption may reduce liquidity and cash runway, against a $4.7M first-half net loss reported in the Q2 10-Q.

  • Restrictions and Claims Released

    The redemption agreement includes a mutual release of claims relating to the Series C Preferred and related transaction documents, plus indemnification obligations of the Company in favor of Shakawe Capital LLC.


Analysis · LABT · Life Sciences

The company spent $1,270,970 of cash on hand to buy back and cancel all 127,097 Series C Preferred shares at their $10.00 face value. That removes the conversion overhang — no common shares will be issued on conversion — and clears the financing restrictions tied to the instrument, leaving no preferred stock and no borrowed debt. The trade-off is liquidity: for a clinical-stage company that reported a $4.7M first-half net loss and unremediated material weaknesses in internal controls, $1.27M is a meaningful slice of the balance sheet, and the press release itself flags that using cash for the redemption may shorten the cash runway. The redemption closed November 4, 2026, so the cash is already out the door.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LABT was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $985.8K. The 52-week trading range was $0.17 to $98.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LABT - Latest Insights

LABT
Sep 28, 2026, 5:49 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $0.4104 info
Change: -$0.6596 (-62%) info
Market Cap: $985.791K info
LABT
Sep 24, 2026, 8:02 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.80
Real-time Price: $0.4104 info
Change: -$1.39 (-77%) info
Market Cap: $985.791K info
LABT
Sep 18, 2026, 5:30 PM EDT
Filing Type: S-1
Importance Score:
7
Price at Filing: $1.94
Real-time Price: $0.4104 info
Change: -$1.53 (-79%) info
Market Cap: $985.791K info
LABT
Aug 13, 2026, 9:36 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.28
Real-time Price: $0.4104 info
Change: -$1.87 (-82%) info
Market Cap: $985.791K info
LABT
Aug 10, 2026, 5:13 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $2.36
Real-time Price: $0.4104 info
Change: -$1.95 (-83%) info
Market Cap: $985.791K info